Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iberdomide in Intermediate- and High-Risk Smoldering Myeloma (SMM) Patients
NCT04776395Phase 2Recruiting
- Sponsor
- Emory University
- Start
- Jul 2021
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of iberdomide in smoldering multiple myeloma (SMM), sponsored by Emory University. Started Jul 2021; status: recruiting.
02
Drugs
iberdomide
03
Conditions
smoldering multiple myeloma (SMM)
Beyond the preview
Go deeper on NCT04776395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04776395.